147 related articles for article (PubMed ID: 24369246)
21. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
22. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS
Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968
[TBL] [Abstract][Full Text] [Related]
23. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
24. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.
Chen J; Guo T; Zhang L; Qin LX; Singer S; Maki RG; Taguchi T; Dematteo R; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2012 Feb; 51(2):186-95. PubMed ID: 22076958
[TBL] [Abstract][Full Text] [Related]
25. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
26. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
27. Biological and genetic characteristics of tumor-initiating cells in colon cancer.
Ieta K; Tanaka F; Haraguchi N; Kita Y; Sakashita H; Mimori K; Matsumoto T; Inoue H; Kuwano H; Mori M
Ann Surg Oncol; 2008 Feb; 15(2):638-48. PubMed ID: 17932721
[TBL] [Abstract][Full Text] [Related]
28. CD133 gene overexpression is frequently observed in early colorectal carcinoma.
Hibi K; Sakata M; Sakuraba K; Shirahata A; Goto T; Mizukami H; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
Hepatogastroenterology; 2009; 56(93):995-7. PubMed ID: 19760928
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
30. Establishment of pancreatic cancer stem cells by flow cytometry and their biological characteristics.
Li D; Su D; Xue L; Liu Y; Pang W
Int J Clin Exp Pathol; 2015; 8(9):11218-23. PubMed ID: 26617845
[TBL] [Abstract][Full Text] [Related]
31. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
32. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
33. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
34. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
36. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis.
Yang K; Chen XZ; Zhang B; Yang C; Chen HN; Chen ZX; Zhou ZG; Chen JP; Hu JK
Int J Biol Markers; 2011; 26(3):173-80. PubMed ID: 21786247
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery.
Nakamura K; Iinuma H; Aoyagi Y; Shibuya H; Watanabe T
Oncology; 2010; 78(5-6):309-15. PubMed ID: 20616575
[TBL] [Abstract][Full Text] [Related]
38. Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor.
Williamson SC; Hepburn AC; Wilson L; Coffey K; Ryan-Munden CA; Pal D; Leung HY; Robson CN; Heer R
PLoS One; 2012; 7(11):e48944. PubMed ID: 23145034
[TBL] [Abstract][Full Text] [Related]
39. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines.
Dong TT; Zhou HM; Wang LL; Feng B; Lv B; Zheng MH
Ann Surg Oncol; 2011 Jun; 18(6):1797-804. PubMed ID: 21267784
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
